RatingAug 11, 2026, 08:02 AM
Teva's Corporate Credit Rating Upgraded to Baa3 by Moody's
AI Summary
Teva Pharmaceutical Industries Ltd. announced that Moody's Ratings has upgraded its corporate credit rating to Baa3 from Ba1, achieving investment-grade status with a stable outlook. Moody's cited Teva's successful growth strategy, including innovative products, an expanded pipeline, and continued debt reduction supported by earnings growth. Teva's CFO, Eli Kalif, highlighted this as a major milestone in the company's transformation and a validation of its "Pivot to Growth" strategy, enhancing financial flexibility and access to a broader investor base. This upgrade follows a similar action by Fitch Ratings in May 2026.
Key Highlights
- Moody's Ratings upgraded Teva's corporate credit rating to Baa3 from Ba1.
- The new Baa3 rating is considered investment grade.
- Moody's assigned a stable outlook to the upgraded rating.
- Upgrade reflects success of growth strategy, expanded pipeline, and debt reduction.
- Moody's noted revenue diversity, improving operating margins, and solid free cash flow.
- This follows a recent upgrade by Fitch Ratings in May 2026.
Price Impact
More from TEVA